Brendan Pang Nghee Kheem MBBS (Singapore), FRCPath (UK)
1. Clinical Assistant Professor, Clinician-Educator tract, Department of Pathology, Yong Loo Lin medical school, National University of Singapore
2. Senior Consultant, Department of Pathology, National University Hospital
3. Laboratory Section Director, Diagnostic Molecular Oncology Centre, Department of Pathology, National University Hospital
4. Principal Associate, Cancer Science Institute
Academic qualifications (Indicate institution’s name and year degree awarded)
1. MBBS, 2003, National University of Singapore
2. FRCPath, 2009, Royal College of Pathologists (UK)
Dr Brendan Pang obtained the FRCPath (UK) and qualified as a histopathologist in Singapore. He then trained in the Diagnostic Molecular Oncology Centre (DMOC), a College of American Pathologists (CAP) accredited molecular diagnostic laboratory under the mentorship of Professor Manuel Salto-Tellez in 2009. He furthered his training in molecular pathology as a visiting scholar at the University of Pittsburgh Medical Centre’s (UPMC) Molecular Anatomic Pathology (MAP) laboratory, Presbyterian Hospital, under Dr Marina Nikiforova, then chair-elect of the solid tumours sub-division of the Association of Molecular pathology (AMP) and returned to Singapore as the Laboratory Director of DMOC in 2011. He was appointed as a Principal Associate at the Cancer Science Institute (CSI) in 2014 and has had research collaborations with the Genome Institute of Singapore (GIS) and other PIs from the Yong Loo Lin School of Medicine. Dr Pang then undertook a second fellowship attachment to the Center for Cancer Research and Cell Biology (CCRCB) in Belfast UK in 2015 to study the deployment of Next Generation Sequencing (NGS) in the setting of academic-industry partnerships. Dr Pang's research interests lie in the development of novel biomarker assays using molecular platforms. As a member of the International Association for the Study of Lung Cancer (IASLC) and the Lung Cancer Consortium of Singapore (LCCS), as well as the Novel Agents Committee for Cancer (NACC), Dr Pang is delighted to bring his expertise into the Parkway-Pantai group for the benefit of oncology practice in the private sector.
Super-enhancer-associated MEIS1 promotes transcriptional dysregulation in Ewing sarcoma in co-operation with EWS-FLI1. Lin L, Huang M, Shi X, Mayakonda A, Hu K, Jiang YY, Guo X, Chen L, Pang B, Doan N, Said JW, Xie J, Gery S, Cheng X, Lin Z, Li J, Berman BP, Yin D, Lin DC, Koeffler HP. Nucleic Acids Res. 2018 Nov 28. doi:10.1093/nar/gky1207. [Epub ahead of print] PMID: 30496486
Combined hepatocellular carcinoma and high grade neuroendocrine carcinoma with EWSR1 gene rearrangement. Chuah KL, Pang B, Lim D, Lee CK, Chau CY. Pathology. 2018 Dec;50(7):779-782. doi: 10.1016/j.pathol.2018.07.005. Epub 2018 Oct 9. No abstract available. PMID: 30314647
Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies. Saei A, Palafox M, Benoukraf T, Kumari N, Jaynes PW, Iyengar PV, Muñoz-Couselo E, Nuciforo P, Cortés J, Nötzel C, Kumarakulasinghe NB, Richard JLC, Bin Adam Isa ZF, Pang B, Guzman M, Siqin Z, Yang H, Tam WL, Serra V, Eichhorn PJA. J Exp Med. 2018 Jul 2;215(7):1913-1928. doi: 10.1084/jem.20171960. Epub 2018 Jun 7. PMID: 29880484
Cell Recognition Molecule L1 Regulates Cell Surface Glycosylation to Modulate Cell Survival and Migration. Shi G, Du Y, Li Y, An Y, He Z, Lin Y, Zhang R, Yan X, Zhao J, Yang S, Brendan PNK, Liu F. Int J Med Sci. 2017 Sep 30;14(12):1276-1283. doi: 10.7150/ijms.20479. eCollection 2017. PMID: 29104485
Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study. Heong V, Syn NL, Lee XW, Sapari NS, Koh XQ, Adam Isa ZF, Sy Lim J, Lim D, Pang B, Thian YL, Ng LK, Wong AL, Soo RA, Yong WP, Chee CE, Lee SC, Goh BC, Soong R, Tan DSP. Int J Cancer. 2018 May 1;142(9):1890-1900. doi: 10.1002/ijc.31091. Epub 2017 Oct 17. PMID: 28994108
Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. Alvi MA, Loughrey MB, Dunne P, McQuaid S, Turkington R, Fuchs MA, McGready C, Bingham V, Pang B, Moore W, Maxwell P, Lawler M, James JA, Murray GI, Wilson RH, Salto-Tellez M. Br J Cancer. 2017 Jun 8. doi: 10.1038/bjc.2017.168. [Epub ahead of print] PMID: 28595259
USP26 regulates TGF-β signaling by deubiquitinating and stabilizing SMAD7. Kit Leng Lui S, Iyengar PV, Jaynes P, Isa ZFBA, Pang B, Tan TZ, Eichhorn PJA. EMBO Rep. 2017 May;18(5):797-808. doi: 10.15252/embr.201643270. Epub 2017 Apr 5. PMID: 28381482
Identification of a Novel SYK/c-MYC/MALAT1 Signaling Pathway and Its Potential Therapeutic Value in Ewing Sarcoma. Sun H, Lin DC, Cao Q, Pang B, Gae DD, Lee VKM, Lim HJ, Doan N, Said JW, Gery S, Chow M, Mayakonda A, Forscher C, Tyner JW, Koeffler HP. Clin Cancer Res. 2017 Mar 23. doi: 10.1158/1078-0432.CCR-16-2185. [Epub ahead of print] PMID: 28336564
Tissue-based next generation sequencing: application in a universal healthcare system. Hynes SO, Pang B, James JA, Maxwell P, Salto-Tellez M Br J Cancer. 2017 Feb 28;116(5):553-560. doi: 10.1038/bjc.2016.452. Review.
EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction. Kumarakulasinghe NB, Syn N, Soon YY, Asmat A, Zheng H, Loy EY, Pang B, Soo RA Oncotarget. 2016 Dec 20;7(51):85542-85550. doi: 10.18632/oncotarget.13458.
Low Levels of NDRG1 in Nerve Tissue Are Predictive of Severe Paclitaxel-Induced Neuropathy. Sundar R, Jeyasekharan AD, Pang B, Soong RC, Kumarakulasinghe NB, Ow SG, Ho J, Lim JS, Tan DS, Wilder-Smith EP, Bandla A, Tan SS, Asuncion BR, Fazreen Z, Hoppe MM, Putti TC, Poh LM, Goh BC, Lee SC. PLoS One. 2016 Oct 7;11(10):e0164319. doi: 10.1371/journal.pone.0164319.
CEACAM6 is upregulated by Helicobacter pylori CagA and is a biomarker for early gastric cancer. Roy RK, Hoppe MM, Srivastava S, Samanta A, Sharma N, Tan KT, Yang H, Voon DC, Pang B, Teh M, Murata-Kamiya N, Hatakeyama M, Chang YT, Yong WP, Ito Y, Ho KY, Tan P, Soong R, Koeffler PH, Yeoh KG, Jeyasekharan AD. Oncotarget. 2016 Aug 23;7(34):55290-55301. doi: 10.18632/oncotarget.10528.
TRPV4 Regulates Breast Cancer Cell Extravasation, Stiffness and Actin Cortex. Lee WH, Choong LY, Mon NN, Lu S, Lin Q, Pang B, Yan B, Krishna VS, Singh H, Tan TZ, Thiery JP, Lim CT, Tan PB, Johansson M, Harteneck C, Lim YP. Sci Rep. 2016 Jun 13;6:27903. doi: 10.1038/srep27903.
Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer. Tan CL, Lim TH, Lim TKh, Tan DS, Chua YW, Ang MK, Pang B, Lim CT, Takano A, Lim AS, Leong MC, Lim WT. Oncotarget. 2016 Apr 26;7(17):23251-62. doi: 10.18632/oncotarget.8136.
CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling. Sun H, Lin DC, Cao Q, Guo X, Marijon H, Zhao Z, Gery S, Xu L, Yang H, Pang B, Lee VK, Lim HJ, Doan N, Said JW, Chu P, Mayakonda A, Thomas T, Forscher C, Baloglu E, Shacham S, Rajalingam R, Koeffler HP. Cancer Res. 2016 May 1;76(9):2687-97. doi: 10.1158/0008-5472.CAN-15-1572.
Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. Wong AL, Lim JS, Sinha A, Gopinathan A, Lim R, Tan CS, Soh T, Venkatesh S, Titin C, Sapari NS, Lee SC, Yong WP, Tan DS, Pang B, Wang TT, Zee YK, Soong R, Trnkova Z, Lathia C, Thiery JP, Wilhelm S, Jeffers M, Goh BC. J Transl Med. 2015 Feb 12;13:57. doi: 10.1186/s12967-015-0405-4.